Health Canada approves clobetasol propionate ophthalmic suspension 0.05% for post–cataract surgery inflammation and pain

Health Canada has approved clobetasol propionate ophthalmic suspension 0.05% (CLOBIVIS; Apotex Inc.) for the treatment of postoperative inflammation and pain following cataract surgery, according to a company announcement. The decision introduces a high-potency corticosteroid formulated with nanoparticle technology into the Canadian ophthalmic postoperative care landscape.

Corticosteroids remain a cornerstone of postoperative management; however, differences in potency, formulation, and tolerability continue to shape prescribing decisions.

Trial and Regulatory Overview

The Health Canada approval appears to be based on clinical data previously generated for clobetasol propionate ophthalmic formulations evaluated in postoperative inflammation and pain following cataract surgery. While the press release did not specify trial identifiers or detailed efficacy outcomes, prior phase 2 and phase 3 studies of similar formulations have demonstrated that topical corticosteroids can significantly reduce anterior chamber inflammation and ocular pain compared with vehicle controls.¹

Clobetasol propionate is classified as a superpotent corticosteroid in dermatologic use, and its ophthalmic adaptation raises important considerations regarding both efficacy and safety. The nanoparticle suspension technology is designed to improve drug dispersion and ocular surface residence time, potentially enhancing bioavailability and dosing consistency. However, peer-reviewed, head-to-head comparative data with existing ophthalmic corticosteroids (eg, prednisolone acetate, difluprednate, loteprednol) were not cited in the company communication.

No new safety signals were disclosed in the announcement. As with other topical ophthalmic corticosteroids, class-related adverse effects are expected to include IOP elevation, delayed epithelial healing, and increased susceptibility to infection.² Clinicians are advised to consult the full product monograph for prescribing details.

Clinical Context

Cataract surgery is among the most commonly performed surgical procedures worldwide, with millions of cases annually.³ Although generally safe and effective, postoperative inflammation is nearly universal and, if inadequately controlled, can contribute to complications such as cystoid macular edema, pain, and delayed visual recovery.

Standard postoperative regimens typically include topical corticosteroids, often in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) and antibiotics.⁴ The choice of corticosteroid depends on multiple factors, including potency, dosing frequency, tolerability, and patient-specific risk factors such as glaucoma or steroid responsiveness.

Difluprednate 0.05% and prednisolone acetate 1% are widely used in North America due to their established efficacy profiles.⁵ Loteprednol formulations are often selected for patients at higher risk of steroid-induced IOP elevation due to their ester-based metabolism and potentially improved safety profile.⁶ The introduction of a clobetasol-based ophthalmic suspension may expand options but will require careful evaluation in real-world use.

Drug Background

Clobetasol propionate is a high-potency corticosteroid that exerts anti-inflammatory effects through glucocorticoid receptor activation, leading to inhibition of pro-inflammatory cytokines, reduced leukocyte migration, and stabilization of cellular membranes.² While extensively used in dermatology, its ophthalmic application has been limited, making this approval notable.

The nanoparticle formulation licensed from Formosa Pharmaceuticals aims to address challenges associated with traditional suspensions, including inconsistent drug distribution and the need for vigorous shaking. Enhanced uniformity may improve dosing accuracy, although clinical implications remain to be fully characterized in comparative trials.

Expert Perspective and Interpretation

From a clinical standpoint, the availability of a more potent corticosteroid formulation could be advantageous in cases of severe postoperative inflammation or in patients with suboptimal response to standard therapies. However, higher potency must be balanced against the risk of adverse effects, particularly steroid-induced ocular hypertension.

In the absence of detailed published phase 3 data specific to this formulation in the Canadian population, clinicians may approach adoption cautiously. Comparative effectiveness studies and postmarketing surveillance will be important to define its role relative to established agents.

Limitations and Next Steps

Key limitations include the lack of publicly disclosed trial data in the press release, including study design, sample size, and quantitative efficacy and safety outcomes. Additionally, no direct comparisons with existing corticosteroid therapies were provided.

Future directions should include publication of phase 3 trial results in peer-reviewed journals, real-world evidence studies, and potential subgroup analyses in patients at higher risk of complications. Regulatory status outside Canada, including potential review by the US Food and Drug Administration, remains unclear.

References

1. ClinicalTrials.gov. Evaluation of ophthalmic corticosteroids for post-cataract inflammation. Accessed March 26, 2026. https://clinicaltrials.gov/
   (Note: Specific trial identifier for this formulation could not be verified from the press release.)
2. US Food and Drug Administration. Drug Safety Communication: Ophthalmic corticosteroids labeling and safety. Accessed March 26, 2026. https://www.fda.gov/drugs
3. Lundström M, Barry P, Henry Y, Rosen P, Stenevi U. Visual outcome of cataract surgery; study from the European Registry of Quality Outcomes for Cataract and Refractive Surgery. J Cataract Refract Surg. 2013;39(5):673-679. https://doi.org/10.1016/j.jcrs.2012.11.026
4. American Academy of Ophthalmology. Cataract in the Adult Eye Preferred Practice Pattern. Accessed March 26, 2026. https://www.aao.org/preferred-practice-pattern/cataract-in-adult-eye-ppp
5. Donnenfeld ED, Holland EJ, Stewart RH, et al. Difluprednate ophthalmic emulsion for postoperative inflammation and pain. J Cataract Refract Surg. 2011;37(1):26-34. https://doi.org/10.1016/j.jcrs.2010.07.029
6. Comstock TL, DeCory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Clin Ophthalmol. 2012;6:1299-1306. https://doi.org/10.2147/OPTH.S28953